This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Genentech, Inc.. Active years: 2015-2018.
Company Filing History:
Years Active: 2015-2018
Title: Michelle Nannini: Innovator in Cancer Treatment
Introduction
Michelle Nannini is a prominent inventor based in South San Francisco, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of new therapeutic combinations. With a total of 6 patents, her work focuses on enhancing the efficacy of cancer therapies.
Latest Patents
Nannini's latest patents include groundbreaking inventions related to combinations of AKT inhibitor compounds and chemotherapeutic agents. These inventions provide combinations comprising a compound of formula I or a pharmaceutically acceptable salt thereof, along with one or more agents selected from a list that includes 5-FU, platinum agents, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin, and lapatinib. These combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Career Highlights
Michelle Nannini is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. Her work at Genentech has allowed her to focus on creating effective treatments that can significantly improve patient outcomes in oncology.
Collaborations
Throughout her career, Nannini has collaborated with esteemed colleagues, including Deepak Sampath and Kui Lin. These collaborations have fostered an environment of innovation and have contributed to the advancement of cancer treatment methodologies.
Conclusion
Michelle Nannini's contributions to the field of cancer treatment through her innovative patents and collaborations highlight her role as a leading inventor in the biotechnology sector. Her work continues to pave the way for new therapeutic options for patients battling cancer.